Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00912418 · ClinicalTrials.gov registry record · NA
Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma
A NA study of Melanoma, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT00912418 is a NA study of Melanoma that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 14 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00912418, a NA study of Melanoma, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is an open-label, pilot study of an autologous tumor cell vaccine.
Conditions Studied
Interventions
- BIOLOGICAL autologous tumor cells plus GM-CSF-in Adjuvant
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2000-05-01 |
| Est. Completion | 2002-10-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00912418
The ClinicalTrials.gov registry entry for NCT00912418 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (98% lower). The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which autologous tumor cells plus GM-CSF-in Adjuvant is the first listed.
NCT00912418 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT00912418 about?
NCT00912418 is a clinical study titled "Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma". This study is an open-label, pilot study of an autologous tumor cell vaccine.
What is the current status of trial NCT00912418?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2000-05-01. Estimated completion is 2002-10-09.
What conditions does trial NCT00912418 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00912418?
The interventions under investigation include: autologous tumor cells plus GM-CSF-in Adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00912418?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00912418 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
RECRUITING · NA
-
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
RECRUITING · NA
-
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.